On June 5, Qingsong Health (02661.HK) rose 13.24% in regular trading, trading at HKD 24.82/share, with trading volume of HKD 169 million, significantly higher than its recent daily average.

On the news front, the global trustworthy AI narrative continues to intensify. Anthropic recently completed a USD 65 billion funding round at a USD 965 billion valuation, with honesty as its core model upgrade direction, signaling strong capital endorsement of enterprise-grade trustworthy AI. The Hong Kong AI application sector saw elevated sentiment, with Zhipu accumulating over 60% gains recently, as capital accelerated into AI commercialization plays.

Meanwhile, the company recently announced a strategic partnership with premium general practice brand Yi He Ni, embedding its proprietary evidence-based medical agent into high-net-worth health management scenarios. As the first domestic AI medical product to pass the CAICT MedClaw evaluation, Qingsong Health benefits from sector linkage and policy tailwinds, with capital reflowing to drive the rebound from prior lows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)